Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Boehringer Ingelheim
Baxter
Merck
Colorcon
Daiichi Sankyo
Healthtrust
Mallinckrodt
Cipla

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,133,893

« Back to Dashboard

Summary for Patent: 8,133,893
Title:Trazodone and trazodone hydrochloride in purified form
Abstract: A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40.degree. C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. ##STR00001##
Inventor(s): Marchetti; Marcello (Rome, IT), Iacoangeli; Tommaso (Rome, IT), Ciottoli; Giovanni Battista (Rome, IT), Biondi; Giuseppe (Castel Gandolfo, IT)
Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (Rome, IT)
Application Number:12/513,048
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 8,133,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-002 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Pragma Pharms Llc DESYREL trazodone hydrochloride TABLET;ORAL 018207-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Pragma Pharms Llc DESYREL trazodone hydrochloride TABLET;ORAL 018207-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Pragma Pharms Llc DESYREL trazodone hydrochloride TABLET;ORAL 018207-003 Mar 25, 1985 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Pragma Pharms Llc DESYREL trazodone hydrochloride TABLET;ORAL 018207-004 Nov 7, 1988 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,133,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2007A1603Aug 03, 2007
PCT Information
PCT FiledJuly 23, 2008PCT Application Number:PCT/EP2008/059640
PCT Publication Date:February 12, 2009PCT Publication Number: WO2009/019133

Non-Orange Book US Patents Family Members for Patent 8,133,893

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,314,236 Trazodone and trazodone hydrochloride in purified form ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,133,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 103597 ➤ Sign Up
Slovenia 2178850 ➤ Sign Up
Portugal 2178850 ➤ Sign Up
Mexico 2010001094 ➤ Sign Up
South Korea 20140133901 ➤ Sign Up
South Korea 101505522 ➤ Sign Up
South Korea 20100046245 ➤ Sign Up
Japan 2017141246 ➤ Sign Up
Japan 2014221788 ➤ Sign Up
Japan 5635401 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Teva
Farmers Insurance
Chinese Patent Office
McKinsey
Federal Trade Commission
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot